{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:22:40Z","timestamp":1782235360835,"version":"3.54.5"},"reference-count":29,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002848","name":"National Agency of Research and Development (ANID-Chile)","doi-asserted-by":"publisher","award":["3220275"],"award-info":[{"award-number":["3220275"]}],"id":[{"id":"10.13039\/501100002848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002848","name":"National Agency of Research and Development (ANID-Chile)","doi-asserted-by":"publisher","award":["124-0688"],"award-info":[{"award-number":["124-0688"]}],"id":[{"id":"10.13039\/501100002848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002848","name":"National Agency of Research and Development (ANID-Chile)","doi-asserted-by":"publisher","award":["022401RP"],"award-info":[{"award-number":["022401RP"]}],"id":[{"id":"10.13039\/501100002848","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DICYT (USACH)","award":["3220275"],"award-info":[{"award-number":["3220275"]}]},{"name":"DICYT (USACH)","award":["124-0688"],"award-info":[{"award-number":["124-0688"]}]},{"name":"DICYT (USACH)","award":["022401RP"],"award-info":[{"award-number":["022401RP"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Cholinergic neuron impairment is a significant cause of cognitive decline in Alzheimer\u2019s disease (AD), making acetylcholinesterase (AChE) a key therapeutic target. AChE inhibitors are principal drugs prescribed to alleviate symptoms in AD patients, while up to 50% of these individuals also suffer from depression, frequently treated with selective serotonin reuptake inhibitors (SSRIs). Due to the multisymptomatic nature of AD, there is a growing interest in developing multitargeted ligands that simultaneously enhance cholinergic and serotonergic tone. This study presents the synthesis of novel ligands based on functionalized piperidines, evaluated through radioligand binding assays at the serotonin transporter (SERT) and AChE and butyrylcholinesterase (BuChE) inhibition. The pharmacological results showed that some compounds exhibited moderate inhibitory activity against AChE, with one compound 19 standing out as the most potent, also displaying a moderate BuChE inhibitory activity, while showing low affinity for SERT. On the other hand, compound 21 displayed an interesting polypharmacological profile, with good and selective activity against BuChE and SERT. The results underscore the difficulty of designing promiscuous ligands for these targets and suggest that future structural modifications could optimize their therapeutic potential in AD.<\/jats:p>","DOI":"10.3390\/molecules30143047","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T10:35:31Z","timestamp":1753094131000},"page":"3047","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Design, Synthesis, and Evaluation of 1-Benzylpiperidine and 1-Benzoylpiperidine Derivatives as Dual-Target Inhibitors of Acetylcholinesterase and Serotonin Transporter for Alzheimer\u2032s Disease"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4417-4294","authenticated-orcid":false,"given":"Juan Pablo","family":"Gonz\u00e1lez-Guti\u00e9rrez","sequence":"first","affiliation":[{"name":"Instituto de Ciencias Aplicadas, Facultad de Ingenier\u00eda, Universidad Aut\u00f3noma de Chile, Talca 3467987, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dami\u00e1n","family":"Castillo-R\u00edos","sequence":"additional","affiliation":[{"name":"Instituto de Ciencias Aplicadas, Facultad de Ingenier\u00eda, Universidad Aut\u00f3noma de Chile, Talca 3467987, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"R\u00edos-Campos","sequence":"additional","affiliation":[{"name":"Electrical Signaling in Plants (ESP) Laboratory, Center of Bioinformatics, Simulation and Modeling (CBSM), Faculty of Engineering, Universidad de Talca, Campus Talca, Avenida Lircay, Talca 3460000, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio Alejandro","family":"Gonz\u00e1lez-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Interno de Medicina, Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Huechuraba 8580000, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1nae","family":"Flores Melivilu","sequence":"additional","affiliation":[{"name":"Carrera de Bioqu\u00edmica, Departamento de Ciencias Qu\u00edmicas y Recursos Naturales, Facultad de Ingenier\u00eda y Ciencias, Universidad de La Frontera, Temuco 4811230, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Hormaz\u00e1bal Uribe","sequence":"additional","affiliation":[{"name":"Laboratorio de Qu\u00edmica Ecol\u00f3gica, Departamento de Ciencias Qu\u00edmicas y Recursos Naturales, Universidad de La Frontera, Temuco 4811230, Chile"},{"name":"Centro de Excelencia de Investigaci\u00f3n Biotecnol\u00f3gica Aplicada al Medio Ambiente (CIBAMA), Universidad de La Frontera, Temuco 4811230, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Moraga-Nicol\u00e1s","sequence":"additional","affiliation":[{"name":"Laboratorio de Qu\u00edmica Ecol\u00f3gica, Departamento de Ciencias Qu\u00edmicas y Recursos Naturales, Universidad de La Frontera, Temuco 4811230, Chile"},{"name":"Centro de Excelencia de Investigaci\u00f3n Biotecnol\u00f3gica Aplicada al Medio Ambiente (CIBAMA), Universidad de La Frontera, Temuco 4811230, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerim","family":"Segura","sequence":"additional","affiliation":[{"name":"Laboratorio de Farmacolog\u00eda Molecular y Qu\u00edmica Medicinal, Facultad de Ingenier\u00eda y Ciencias, Universidad de La Frontera, Temuco 4811230, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Laboratorio de Farmacolog\u00eda Molecular y Qu\u00edmica Medicinal, Facultad de Ingenier\u00eda y Ciencias, Universidad de La Frontera, Temuco 4811230, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5468-4936","authenticated-orcid":false,"given":"Amaury","family":"Far\u00edas-Cea","sequence":"additional","affiliation":[{"name":"Laboratorio de Bioqu\u00edmica y Farmacolog\u00eda Molecular, Escuela de Ciencias, Facultad de Ciencias de la Vida, Universidad Vi\u00f1a del Mar, Vi\u00f1a del Mar 2572007, Chile"},{"name":"Escuela de Educaci\u00f3n, Facultad de Ciencias Jur\u00eddicas, Sociales y de la Educaci\u00f3n, Universidad Vi\u00f1a del Mar, Vi\u00f1a del Mar 2580022, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1n Armando","family":"Pessoa-Mahana","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Org\u00e1nica y Fisicoqu\u00edmica, Facultad de Ciencias Qu\u00edmicas y Farmac\u00e9uticas, Universidad de Chile, Santiago 8380492, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-990X","authenticated-orcid":false,"given":"Miguel Iv\u00e1n","family":"Reyes-Parada","sequence":"additional","affiliation":[{"name":"Instituto de Ciencias Aplicadas, Facultad de Ingenier\u00eda, Universidad Aut\u00f3noma de Chile, Talca 3467987, Chile"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica y Aplicada (CIBAP), Escuela de Medicina, Facultad de Ciencias M\u00e9dicas, Universidad de Santiago de Chile, Santiago 9170022, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0553-1014","authenticated-orcid":false,"given":"Patricio","family":"Iturriaga-V\u00e1squez","sequence":"additional","affiliation":[{"name":"Laboratorio de Farmacolog\u00eda Molecular y Qu\u00edmica Medicinal, Facultad de Ingenier\u00eda y Ciencias, Universidad de La Frontera, Temuco 4811230, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nm0706-780","article-title":"Alzheimer disease: Progress or profit?","volume":"12","author":"Mount","year":"2006","journal-title":"Nat Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/01.wnl.0000295996.54210.69","article-title":"Disease-modifying therapies for Alzheimer disease: Challenges to early intervention","volume":"69","author":"Cummings","year":"2007","journal-title":"Neurology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer\u2019s disease","volume":"6","author":"Yiannopoulou","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: Structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1756285611404470","article-title":"Disease-modifying treatments for Alzheimer\u2019s disease","volume":"4","author":"Galimberti","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/brain\/awl280","article-title":"Therapeutic approaches to Alzheimer\u2019s disease","volume":"129","author":"Klafki","year":"2006","journal-title":"Brain."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer\u2019s disease: A review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_8","first-page":"183","article-title":"Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer\u2019s disease and schizophrenia","volume":"10","author":"Foster","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1021\/acschemneuro.6b00050","article-title":"Synthesis and Behavioral Studies of Chiral Cyclopropanes as Selective \u03b14\u03b22-Nicotinic Acetylcholine Receptor Partial Agonists Exhibiting an Antidepressant Profile. Part III","volume":"7","author":"Onajole","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejmech.2014.08.019","article-title":"Identification and pharmacological characterization of 3,6-diazabicyclo[3.1.1]heptane-3-carboxamides as novel ligands for the \u03b14\u03b22 and \u03b16\/\u03b13\u03b22\u03b23 nicotinic acetylcholine receptors (nAChRs)","volume":"86","author":"Strachan","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_11","unstructured":"Barrett, K.E., Boitano, S., Barman, S.M., Brooks, H.L., and Michael Weitz, B.P.K. (2012). Ganong\u2019 s Review of Medical Physiology, McGraw Hill. [24th ed.]."},{"key":"ref_12","first-page":"1479","article-title":"Cholinesterase inhibitors as Alzheimer\u2019s therapeutics (Review)","volume":"20","author":"Sharma","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.coph.2005.01.014","article-title":"Acetylcholinesterase: \u201cclassical\u201d and \u201cnon-classical\u201d functions and pharmacology","volume":"5","author":"Silman","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14756366.2018.1545766","article-title":"Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer\u2019s disease therapy","volume":"34","author":"Refouvelet","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"108352","DOI":"10.1016\/j.neuropharm.2020.108352","article-title":"Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease","volume":"190","author":"Marucci","year":"2021","journal-title":"Neuropharmacology."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","article-title":"Galantamine \u2014 a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer\u2019s Disease","volume":"8","author":"Lilienfeld","year":"2002","journal-title":"CNS Drug Rev."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez, M., Gobartt, A.L., and Bala\u00f1\u00e1, M. (2010). Behavioural symptoms in patients with Alzheimer\u2019s disease and their association with cognitive impairment. BMC Neurol., 10.","DOI":"10.1186\/1471-2377-10-87"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3233\/JAD-161247","article-title":"Efficacy of Antidepressants for Depression in Alzheimer\u2019s Disease: Systematic Review and Meta-Analysis. Leoutsakos J-M, editor","volume":"58","author":"Orgeta","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","article-title":"Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management","volume":"367","author":"Singh","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1800024","DOI":"10.1002\/ardp.201800024","article-title":"Synthesis and biological evaluation of potential acetylcholinesterase inhibitors based on a benzoxazine core","volume":"351","author":"Quiroz","year":"2018","journal-title":"Arch. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"112674","DOI":"10.1016\/j.ejmech.2020.112674","article-title":"Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability","volume":"208","author":"Giancola","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2400387","DOI":"10.1002\/ardp.202400387","article-title":"First in class pyrrolo[2,3-d]pyrimidine derivatives fused to fluorobenzylpiperidines as dual ligands of acetylcholinesterase and histamine H3 receptor","volume":"358","author":"Werner","year":"2025","journal-title":"Arch. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zhou, S., and Huang, G. (2022). The biological activities of butyrylcholinesterase inhibitors. Biomed. Pharmacother., 146.","DOI":"10.1016\/j.biopha.2021.112556"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e56427","DOI":"10.7554\/eLife.56427","article-title":"Chemical and structural investigation of the paroxetine-human serotonin transporter complex","volume":"9","author":"Coleman","year":"2020","journal-title":"eLife."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/14786419.2021.1872075","article-title":"Acetylcholinesterase inhibitory activity from Amaryllis belladonna growing in Chile: Enzymatic and molecular docking studies","volume":"36","author":"Mella","year":"2022","journal-title":"Nat. Prod. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal. Biochem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"W324","DOI":"10.1093\/nar\/gkae300","article-title":"SwissDock 2024: Major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina","volume":"52","author":"Bugnon","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/14\/3047\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:13:14Z","timestamp":1760033594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/14\/3047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":29,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["molecules30143047"],"URL":"https:\/\/doi.org\/10.3390\/molecules30143047","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}